Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M D'Incalci

Showing results (61-70 of 339) with videos related to

Pageof 34
Sort By:
European Journal of Cancer|December 1, 1978
Adriamycin in ovarian cancer patients resistant to cyclophosphamideG Bolis, M D'Incalci, F Gramellini, et al.
Experimental Cell Research|September 15, 1996
Changes in cyclins and cyclin-dependent kinases induced by DNA damaging agents in a human ovarian cancer cell line expressing mutated or wild-type P53F Vikhanskaya, E Erba, M D'Incalci, et al.
Lancet (London, England)|January 1, 1983
Transplacental passage of doxorubicinM d'Incalci, M Broggini, M Buscaglia, et al.
European Journal of Cancer (Oxford, England : 1990)|February 1, 1997
Combination of the new minor groove alkylator tallimustine and melphalanG Tagliabue, C Filippini, P Ubezio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 1992
Antitumor activity of 1,4-bis (2'-chloroethyl)-1,4-diazabicyclo-[2.2.1] heptane dimaleate (Dabis Maleate) in M5076 and its subline resistant to cyclophosphamide M5/CTXG Tagliabue, S Filippeschi, H Hendricks, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
Sequential administration of dacarbazine and fotemustine in patients with disseminated malignant melanoma--an effective combination with unexpected toxicityS Aamdal, B Gerard, T Bohman, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1990
Flavone acetic acid antitumour activity against a mouse pancreatic adenocarcinoma is mediated by natural killer cellsG Damia, G Tagliabue, P Allavena, et al.
Nucleic Acids Research|March 25, 1994
Introduction of wild-type p53 in a human ovarian cancer cell line not expressing endogenous p53F Vikhanskaya, E Erba, M D'Incalci, et al.
International Journal of Cancer|July 17, 1995
Comparison of cell-cycle phase perturbations induced by the DNA-minor-groove alkylator tallimustine and by melphalan in the SW626 cell lineE Erba, E Mascellani, A Pifferi, et al.
European Journal of Cancer & Clinical Oncology|December 1, 1981
Influence of ascites on the pharmacokinetics of hexamethylmelamine and N-demethylated metabolites in ovarian cancer patientsM D'Incalci, G Beggiolin, C Sessa, et al.
Pageof 34

Showing results (61-70 of 339) with videos related to

Sort By:
Pageof 34
European Journal of Cancer|December 1, 1978
Adriamycin in ovarian cancer patients resistant to cyclophosphamideG Bolis, M D'Incalci, F Gramellini, et al.
Experimental Cell Research|September 15, 1996
Changes in cyclins and cyclin-dependent kinases induced by DNA damaging agents in a human ovarian cancer cell line expressing mutated or wild-type P53F Vikhanskaya, E Erba, M D'Incalci, et al.
Lancet (London, England)|January 1, 1983
Transplacental passage of doxorubicinM d'Incalci, M Broggini, M Buscaglia, et al.
European Journal of Cancer (Oxford, England : 1990)|February 1, 1997
Combination of the new minor groove alkylator tallimustine and melphalanG Tagliabue, C Filippini, P Ubezio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 1992
Antitumor activity of 1,4-bis (2'-chloroethyl)-1,4-diazabicyclo-[2.2.1] heptane dimaleate (Dabis Maleate) in M5076 and its subline resistant to cyclophosphamide M5/CTXG Tagliabue, S Filippeschi, H Hendricks, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
Sequential administration of dacarbazine and fotemustine in patients with disseminated malignant melanoma--an effective combination with unexpected toxicityS Aamdal, B Gerard, T Bohman, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1990
Flavone acetic acid antitumour activity against a mouse pancreatic adenocarcinoma is mediated by natural killer cellsG Damia, G Tagliabue, P Allavena, et al.
Nucleic Acids Research|March 25, 1994
Introduction of wild-type p53 in a human ovarian cancer cell line not expressing endogenous p53F Vikhanskaya, E Erba, M D'Incalci, et al.
International Journal of Cancer|July 17, 1995
Comparison of cell-cycle phase perturbations induced by the DNA-minor-groove alkylator tallimustine and by melphalan in the SW626 cell lineE Erba, E Mascellani, A Pifferi, et al.
European Journal of Cancer & Clinical Oncology|December 1, 1981
Influence of ascites on the pharmacokinetics of hexamethylmelamine and N-demethylated metabolites in ovarian cancer patientsM D'Incalci, G Beggiolin, C Sessa, et al.
Pageof 34